References
- Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016; 134:441–50.
- Aekplakorn W. Thai National Health Examination Survey VI (NHES VI). [Accessed 2023 Oct 13]. Available from: https://www. hsri.or.th/media/printed-matter/detail/13443
- Cheng RZ, Vivek B, Tara C. Comparison of routine and automated office blood pressure measurement. Blood Press Monit. 2019; 24:174–8.
- Roubsanthisuk W, Wongsurin U, Saravich S, Buranakitjaroen P. Blood pressure determination by traditionally trained personnel is less reliable and tends to underestimate the severity of moderate to severe hypertension. Blood Press Monit. 2007; 12:61–8.
- Muntner P, Shimbo D, Carey RM, Charleston JB, Gaillard T, Misra S, et al. Measurement of blood pressure in humans: a scientific statement from the American Heart Associations. Hypertension. 2019; 73:e35–e66.
- Stergiou GS, Palatini P, Parati G, O’Brien E, Januszewicz A, Lurbe E, et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021; 39:1293–302.
- Fedorowski A, Ricci F, Hamrefors V, Sandau KE, Hwan Chung T, Muldowney JAS, et al. Orthostatic hypotension: management of a complex, but common, medical problem. Circ Arrhythm Electro-physiol. 2022; 15:e010573. doi: 10.1161/CIRCEP.121.010573
- Kunanon S, Roubsanthisuk W, Chattranukulchai P, Sangwatanaroj S, Ophascharoensuk V, Sitthisook S, et al. 2022 Thai Hypertension Society guidelines on home blood pressure monitoring. J Clin Hypertens (Greenwich). 2022; 24:1139–46.
- Parati G, Stergiou G, O’Brien E, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014; 32:1359–66.
- Kario K, Hoshide S, Mizuno H, Kabutoya T, Nishizawa M, Yoshida T, et al. Nighttime blood pressure phenotype and cardiovascular prognosis. Practitioner-based nationwide JAMP study. Circulation. 2020; 142:1810–20.
- Tomitani N, Wanthong S, Roubsanthisuk W, Buranakitjaroen P, Hoshide S, Kario K. Differences in ambulatory blood pressure profiles between Japanese and Thai patients with hypertension/suspected hypertension. J Clin Hypertens (Greenwich). 2021; 23:614–20.
- Kunanon S, Chattranukulchai P, Chotruangnapa C, Kositanurit W, Methavigul K, Boonyasirinant T, et al. 2019 Thai guidelines on the treatment of hypertension: executive summary. J Med Assoc Thai. 2021; 104:1729–38.
- Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020; 75:1334–57.
- Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42:3227–337.
- Guideline for the pharmacological treatment of hypertension in adults [Internet]. Geneva: World Health Organization; 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK573631/
- Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023; 41:1874–2071.
- Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies C. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360:1903–13.
- Lacey B, Lewington S, Clarke R, Kong XL, Chen Y, Guo Y, et al. Age-specific association between blood pressure and vascular and non-vascular chronic diseases in 0.5 million adults in China: a prospective cohort study. Lancet Glob Health. 2018; 6:e641–e649.
- Liu N, Yang JJ, Meng R, Pan XF, Zhang X, He M, et al. Associations of blood pressure categories defined by 2017 ACC/AHA guidelines with mortality in China: pooled results from three prospective cohorts. Eur J Prev Cardiol. 2020; 27:345–54.
- Choi WJ, Lee HS, Hong JH, Chang HJ, Lee JW. Comparison of the JNC7 and 2017 American College of Cardiology/American Heart Association guidelines for the management of hypertension in Koreans: analysis of two independent nationwide population-based studies. Int J Environ Res Public Health. 2019; 16:5134. doi: 10.3390/ijerph16245134
- Kim YT, Chung HJ, Park BR, Kim YY, Lee JH, Kang DR. Risk of cardiovascular disease and chronic kidney disease according to 2017 blood pressure categories in diabetes mellitus. Hypertension. 2020; 76:766–75.
- Hatano Y, Yano Y, Fujimoto S, Sato Y, Iseki K, Konta T, et al. The population-attributable fraction for premature mortality due to cardiovascular disease associated with stage 1 and 2 hypertension among Japanese. Am J Hypertens. 2021; 34:56–63.
- Lawes CM, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H, et al. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens. 2003; 21:707–16.
- SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373:2103–16.
- Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021; 385:1268–79.
- Charchar FJ, Prestes PR, Mills C, Ching SM, Neupane D, Marques FZ, et al. Lifestyle management of hypertension: International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension. J Hypertens. 2024; 42:23–49.
- Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997; 336:1117–24.
- Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001; 344:3–10.
- Gibbs J, Gaskin E, Ji C, Miller MA, Cappuccio FP. The effect of plant-based dietary patterns on blood pressure: a systematic review and meta-analysis of controlled intervention trials. J Hypertens. 2021; 39:23–37.
- Dempsey PC, Larsen RN, Dunstan DW, Owen N, Kingwell BA. Sitting less and moving more: implications for hypertension. Hypertension. 2018; 72:1037–46.
- Anderson BO, Berdzuli N, Ilbawi A, Kestel D, Kluge HP, Krech R, et al. Health and cancer risks associated with low levels of alcohol consumption. Lancet Public Health. 2023; 8:e6–e7.
- Skotsimara G, Antonopoulos AS, Oikonomou E, Siasos G, Ioakeimidis N, Tsalamandris S, et al. Cardiovascular effects of electronic cigarettes: a systematic review and meta-analysis. Eur J Prev Cardiol. 2019; 26:1219–28.
- Saffar Soflaei S, Darroudi S, Tayefi M, Nosrati Tirkani A, Moohebati M, Ebrahimi M, et al. Hookah smoking is strongly associated with diabetes mellitus, metabolic syndrome and obesity: a population-based study. Diabetol Metab Syndr. 2018; 10:33. doi: 10.1186/s13098-018-0335-4
- Albus C, Waller C, Fritzsche K, Gunold H, Haass M, Hamann B, et al. Significance of psychosocial factors in cardiology: update 2018: position paper of the German Cardiac Society. Clin Res Cardiol. 2019; 108:1175–96.
- Liu MY, Li N, Li WA, Khan H. Association between psychosocial stress and hypertension: a systematic review and meta-analysis. Neurol Res. 2017; 39:573–80.
- Schneider JK, Reangsing C, Willis DG. Effects of transcendental meditation on blood pressure: a meta-analysis. J Cardiovasc Nurs. 2022; 37:E11–E21.
- Shi L, Zhang D, Wang L, Zhuang J, Cook R, Chen L. Meditation and blood pressure: a meta-analysis of randomized clinical trials. J Hypertens. 2017; 35:696–706.
- Fu J, Liu Y, Zhang L, Zhou L, Li D, Quan H, et al. Nonpharmacologic interventions for reducing blood pressure in adults with prehypertension to established hypertension. J Am Heart Assoc. 2020; 9:e016804. doi: 10.1161/JAHA.120.016804
- Im-Oun S, Kotruchin P, Thinsug P, Mitsungnern T, Techa-Atik P, Pongchaiyakul C. Effect of Thai instrumental folk music on blood pressure: a randomized controlled trial in stage-2 hypertensive patients. Complement Ther Med. 2018; 39:43–8.
- Hahad O, Rajagopalan S, Lelieveld J, Sørensen M, Kuntic M, Daiber A, et al. Noise and air pollution as risk factors for hypertension: part II-pathophysiologic insight. Hypertension. 2023; 80:1384–92.
- Wojciechowska W, Januszewicz A, Drożdż T, Rojek M, Bączalska J, Terlecki M, et al. Blood pressure and arterial stiffness in association with aircraft noise exposure: long-term observation and potential effect of COVID-19 lockdown. Hypertension. 2022; 79:325–34.
- Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Letkowitz MP. Blood-pressure reduction with LCZ 696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomized, double-blind, placebo-controlled, active comparator study. Lancet. 2010; 375:1255–66.
- Chua SK, Lai WT, Chen LC, Hung HF. The antihypertensive effects and safety of LCZ696 in patients with hypertension: a systemic review and meta-analysis of randomized controlled trials. J Clin Med. 2021; 10:2824. doi: 10.3390/jcm10132824
- Sanidas EA, Papadopoulos DP, Hatziagelaki E, Grassos C, Velliou M, Barbetseas J. Sodium glucose cotransporter 2 (SGLT2) inhibitors across the spectrum of hypertension. Am J Hypertens. 2020; 33:207–13.
- Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized controlled trials with 22,528 patients. J Am Heart Assoc. 2017; 6:e004007. doi: 10.1161/JAHA.116.004007
- Ryan D, Acosta A. GLP-1 receptor agonists: nonglycemic clinical effects in weight loss and beyond. Obesity (Silver Spring). 2015; 23:1119–29.
- Sivertsen J, Rosenmeier J, Holst JJ, Vilsbøll T. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol. 2012; 9:209–22.
- Schmieder RE, Wassmann S, Predel HG, Weisser B, Blettenberg J, Gillessen A, et al. Improved persistence to medication, decreased cardiovascular events and reduced all-cause mortality in hypertensive patients with use of single-pill combinations: results from the START-study. Hypertension. 2023; 80:127–35.
- Mackenzie IS, Rogers A, Poulter NR, Williams B, Brown MJ, Webb DJ, et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomized, open-label, blinded-endpoint clinical trial. Lancet. 2022; 400:1417–25.
- Grassi G, Pisano A, Bolignano D, Seravalle G, D’Arrigo G, Quarti-Trevano F, et al. Sympathetic nerve traffic activation in essential hypertension and its correlates: systematic reviews and meta-analyses. Hypertension. 2018; 72:483–91.
- Sega R, Trocino G, Lanzarotti A, Carugo S, Cesana G, Schiavina R, et al. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). Circulation. 2001; 104:1385–92.
- Briasoulis A, Androulakis E, Palla M, Papageorgiou N, Tousoulis D. White-coat hypertension and cardiovascular events: a meta-analysis. J Hypertens. 2016; 34:593–9.
- Mancia G, Bombelli M, Facchetti R, Madotto F, Quarti-Trevano F, Polo Friz H, et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension. 2009; 54:226–32.
- Mancia G, Bombelli M, Facchetti R, Madotto F, Quarti-Trevano F, Grassi G, et al. Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension. J Hypertens. 2009; 27:1672–8.
- Mancia G, Facchetti R, Bombelli M, Cuspidi C, Grassi G. White-coat hypertension: pathophysiological and clinical aspects: Excellence Award for Hypertension Research 2020. Hypertension. 2021; 78:1677–88.
- Mancia G, Facchetti R, Parati G, Zanchetti A. Effect of long-term antihypertensive treatment on white-coat hypertension. Hypertension. 2014; 64:1388–98.
- Cuspidi C, Facchetti R, Bombelli M, Sala C, Tadic M, Grassi G, et al. Risk of new-onset metabolic syndrome associated with white-coat and masked hypertension: data from a general population. J Hypertens. 2018; 36:1833–9.
- Palla M, Saber H, Konda S, Briasoulis A. Masked hypertension and cardiovascular outcomes: an updated systematic review and meta-analysis. Integr Blood Press Control. 2018; 11:11–24.
- Tientcheu D, Ayers C, Das SR, McGuire DK, de Lemos JA, Khera A, et al. Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: analysis from the Dallas Heart Study. J Am Coll Cardiol. 2015; 66:2159–69.
- Turnbull F, Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomized trials. Lancet. 2003; 362:1527–35.
- Okamoto R, Kumagai E, Kai H, Shibata R, Ohtsubo T, Kawano H, et al. Effects of lowering diastolic blood pressure to <80 mmHg on cardiovascular mortality and events in patients with coronary artery disease: a systemic review and meta-analysis. Hypertension Res. 2019; 42:650–9.
- Janwanishstaporn S, Karaketklang K, Krittayaphong R. National trend in heart failure hospitalization and outcome under public health insurance system in Thailand 2008–2013. BMC Cardiovasc Disord. 2022; 22:203. doi: 10.1186/s12872-022-02629-2
- Laothavorn P, Hengrussamee K, Kanjanavanit R, Moleerergpoom W, Laorakpongse D, Pachirat O, et al. Thai acute decompensated heart failure registry (Thai ADHERE). Global Heart. 2010; 5:89–95.
- Krittayaphong R, Laothavorn P, Hengrussamee K, Sanguanwong S, Kunjara-Na-Ayudhya R, Rattanasumawong K, et al. Ten-year survival and factors associated with increased mortality in patients admitted for acute decompensated heart failure in Thailand. Singapore Med J. 2020; 61:320–6.
- Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017; 14:591–602.
- Blood Pressure Lowering Treatment Trialists’ Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021; 397:1625–36.
- Raby K, Rocco M, Oparil S, Gilbert ON, Upadhya B. Heart failure primary prevention: what does SPRINT add?: recent advances in hypertension. Hypertension. 2021; 77:1804–14.
- Buakhamsri A, Chirakarnjanakorn S, Sanguanwong S, Porapakkham P, Kanjanavanich R. Heart Failure Council of Thailand (HFCT) 2019 heart failure guideline: pharmacologic treatment of chronic heart failure – part I. J Med Assoc Thai. 2019; 102:240–4.
- Zhang Q, Zhou S, Liu L. Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis. Diabetol Metab Syndr. 2023; 15:118. doi: 10.1186/s13098-023-01092-z
- Jackson AM, Jhund PS, Anand IS, Düngen HD, Lam CSP, Lefkowitz MP, et al. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J. 2021; 42:3741–52.
- Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022; 400:757–67.
- Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014; 370:1383–92.
- Ariyachaipanich A, Buakhamsri A, Phrommintikul A, Chirakarn-janakorn S. 2023 HFCT focused update of the 2019 HFCT heart failure guidelines part 2: diagnosis and management of HFmrEF and HFpEF. J Med Assoc Thai. 2023; 106:1005–14.
- Kario K, Mogi M, Hoshide S. Latest hypertension research to inform clinical practice in Asia. Hypertens Res. 2022; 45:555–72.
- Chirakarnjanakorn S, Krittayaphong R, Chantrarat T, Ratana-sumawong K, Songmuang SB. Heart Failure Council of Thailand (HFCT) 2019 heart failure guideline: comorbidity in heart failure. J Med Assoc Thai. 2019; 102:508–12.
- Miao H, Zou C, Yang S, Chia YC, Van Huynh M, Sogunuru GP. Targets and management of hypertension in heart failure: focusing on the stages of heart failure. J Clin Hypertens (Greenwich). 2022; 24:1218–25.
- Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996; 334:13–8.
- Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, et al. Effects of intensive BP control in CKD. J Am Soc Nephrol. 2017; 28:2812–23.
- Malhotra R, Nguyen HA, Benavente O, Mete M, Howard BV, Mant J, et al. Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: a systematic review and meta-analysis. JAMA Intern Med. 2017; 177:1498–505.
- Ku E, Sarnak MJ, Toto R, McCulloch CE, Lin F, Smogorzewski M, et al. Effect of blood pressure control on long-term risk of end-stage renal disease and death among subgroups of patients with chronic kidney disease. J Am Heart Assoc. 2019; 8:e012749. doi: 10.1161/JAHA.119.012749
- Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ. 2004; 329:828. doi: 10.1136/bmj.38237.585000.7C
- The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997; 349:1857–63.
- Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006; 354:131–40.
- Kent DM, Jafar TH, Hayward RA, Tighiouart H, Landa M, de Jong P, et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol. 2007; 18:1959–65.
- Kidney Disease: Improving Global Outcomes Blood Pressure Work. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021; 99:S1–S87.
- Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013; 369:1892–903.
- ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358:1547–59.
- Elliott WJ. Renovascular hypertension: an update. J Clin Hypertens (Greenwich). 2008; 10:522–33.
- Hicks CW, Clark TWI, Cooper CJ, de Bhailís ÁM, De Carlo M, Green D, et al. Atherosclerotic renovascular disease: a KDIGO (Kidney Disease: Improving Global Outcomes) controversies conference. Am J Kidney Dis. 2022; 79:289–301.
- Halliday A, Bax JJ. The 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018; 55:301–2.
- Pisano A, Mallamaci F, D’Arrigo G, Bolignano D, Wuerzner G, Ortiz A, et al. Blood pressure monitoring in kidney transplantation: a systematic review on hypertension and target organ damage. Nephrol Dial Transplant. 2021; 36:1326–46.
- Alexandrou ME, Ferro CJ, Boletis I, Papagianni A, Sarafidis P. Hypertension in kidney transplant recipients. World J Transplant. 2022; 12:211–22.
- Pisano A, Bolignano D, Mallamaci F, D’Arrigo G, Halimi JM, Persu A, et al. Comparative effectiveness of different antihypertensive agents in kidney transplantation: a systematic review and meta-analysis. Nephrol Dial Transplant. 2020; 35:878–87.
- Potter JF, Robinson TG, Ford GA, Mistri A, James M, Chernova J, et al. Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial. Lancet Neurol. 2009; 8:48–56.
- He J, Zhang Y, Xu T, Zhao Q, Wang D, Chen CS, et al. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA. 2014; 311:479–89.
- Bath PM, Martin RH, Palesch Y, Cotton D, Yusuf S, Sacco R, et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke. 2009; 40:3541–6.
- Lee M, Ovbiagele B, Hong KS, Wu YL, Lee JE, Rao NM, et al. Effect of blood pressure lowering in early ischemic stroke: meta-analysis. Stroke. 2015; 46:1883–9.
- Moullaali TJ, Wang X, Martin RH, Shipes VB, Robinson TG, Chalmers J, et al. Blood pressure control and clinical outcomes in acute intracerebral haemorrhage: a preplanned pooled analysis of individual participant data. Lancet Neurol. 2019; 18:857–64.
- SPS3 Study Group, Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013; 382:507–15.
- Wang X, Arima H, Heeley E, Delcourt C, Huang Y, Wang J, et al. Magnitude of blood pressure reduction and clinical outcomes in acute intracerebral hemorrhage: intensive blood pressure reduction in acute cerebral hemorrhage trial study. Hypertension. 2015; 65:1026–32.
- Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013; 368:2355–65.
- Gong S, Lin C, Zhang D, Kong X, Chen J, Wang C, et al. Effects of intensive blood pressure reduction on acute intracerebral hemorrhage: a systematic review and meta-analysis. Sci Rep. 2017; 7:10694. doi: 10.1038/s41598-017-10892-z
- Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016; 375:1033–43.
- Manning L, Hirakawa Y, Arima H, Wang X, Chalmers J, Wang J, et al. Blood pressure variability and outcome after acute intracerebral haemorrhage: a post-hoc analysis of INTERACT2, a randomised controlled trial. Lancet Neurol. 2014; 13:364–73.
- Zonneveld TP, Richard E, Vergouwen MD, Nederkoorn PJ, de Haan R, Roos YB, et al. Blood pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2018; 7:CD007858. doi: 10.1002/14651858.CD007858.pub2
- Kitagawa K, Yamamoto Y, Arima H, Maeda T, Sunami N, Kanzawa T, et al. Effect of standard vs intensive blood pressure control on the risk of recurrent stroke: a randomized clinical trial and meta-analysis. JAMA Neurol. 2019; 76:1309–18.
- Mant J, McManus RJ, Roalfe A, Fletcher K, Taylor CJ, Martin U, et al. Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST-BP (prevention after stroke–blood pressure) randomised controlled trial. BMJ. 2016; 352:i708. doi: 10.1136/bmj.i708
- Katsanos AH, Filippatou A, Manios E, Deftereos S, Parissis J, Frogoudaki A, et al. Blood pressure reduction and secondary stroke prevention: a systematic review and meta-regression analysis of randomized clinical trials. Hypertension. 2017; 69:171–9.
- Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017; 135:e686–e725.
- Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006; 295:180–9.
- ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981–97.
- Bavry AA, Anderson RD, Gong Y, Denardo SJ, Cooper-Dehoff RM, Handberg EM, et al. Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the International Verapamil-SR/Trandolapril Study. Hypertension. 2010; 55:48–53.
- Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension. 1992; 19:403–18.
- Weidman P, Boehlen LM, deCourtten M. Pathogenesis and treatment of hypertension associated with diabetes mellitus. Am Heart J. 1993; 125:1458–63.
- Simonson DC. Etiology and prevalence of hypertension in diabetic patients. Diabetes Care. 1988; 11:821–7.
- de Boer IH, Bangalore S, Benetos A, Davis AM, Michos ED, Muntner P, et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care. 2017; 40:273–84.
- Bunnag P, Plengvidhya N, Deerochanawong C, Suwanwalaikorn S, Kosachunhanun N, Benjasuratwong Y, et al. Thailand diabetes registry project: prevalence of hypertension, treatment and control of blood pressure in hypertensive adults with type 2 diabetes. J Med Assoc Thai. 2006; 89(Suppl 1):S72–S77.
- Naseri MW, Esmat HA, Bahee MD. Prevalence of hypertension in type 2 diabetes mellitus. Ann Med Surg (Lond). 2022; 78:103758. doi: 10.1016/j.amsu.2022.103758
- American Diabetes Association Professional Practice Committee. 10 Cardiovascular disease and risk management: standards of care in diabetes-2024. Diabetes Care. 2024; 47(Suppl 1):S179–S218.
- Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020; 75:285–92.
- Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387:957–67.
- Adamsson Eryd S, Gudbjörnsdottir S, Manhem K, Rosengren A, Svensson AM, Miftaraj M, et al. Blood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study. BMJ. 2016; 354:i4070. doi: 10.1136/bmj.i4070
- Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015; 313:603–15.
- Nazarzadeh M, Bidel Z, Canoy D, Copland E, Bennett DA, Dehghan A, et al. Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis. Lancet Diabetes Endocrinol. 2022; 10:645–54.
- Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017; 35:922–44.
- ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362:1575–85.
- Beddhu S, Chertow GM, Greene T, Whelton PK, Ambrosius WT, Cheung AK, et al. Effects of intensive systolic blood pressure lowering on cardiovascular events and mortality in patients with type 2 diabetes mellitus on standard glycemic control and in those without diabetes mellitus: reconciling results from ACCORD BP and SPRINT. J Am Heart Assoc. 2018; 7:e009326. doi: 10.1161/JAHA.118.009326
- Yang Q, Zheng R, Wang S, Zhu J, Li M, Wang T, et al. Systolic blood pressure control targets to prevent major cardiovascular events and death in patients with type 2 diabetes: a systematic review and network meta-analysis. Hypertension. 2023; 80:1640–53.
- Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39:3021–104.
- Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018; 71:1269–324.
- Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023; 44:4043–140.
- Van Gaal L, Scheen A. Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care. 2015; 38:1161–72.
- Stergiou G, Brunström M, MacDonald T, Kyriakoulis KG, Bursztyn M, Khan N, et al. Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension. J Hypertens. 2022; 40:1847–58.
- Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015; 385:2047–56.
- Beddhu S, Greene T, Boucher R, Cushman WC, Wei G, Stoddard G, et al. Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials. Lancet Diabetes Endocrinol. 2018; 6:555–63.
- Catalá-López F, Macías Saint-Gerons D, González-Bermejo D, Rosano GM, Davis BR, Ridao M, et al. Cardiovascular and renal outcomes of renin-angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses. PLoS Med. 2016; 13:e1001971. doi: 10.1371/journal. pmed.1001971
- Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020; 383:2219–29.
- Pitt B, Filippatos G, Agarwal R. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021; 385:2252–63.
- McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021; 6:148–58.
- Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019; 139:2022–31.
- Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005; 111:1777–83.
- Cepeda M, Pham P, Shimbo D. Status of ambulatory blood pressure monitoring and home blood pressure monitoring for the diagnosis and management of hypertension in the US: an up-to-date review. Hypertens Res. 2023; 46:620–9.
- Omboni S, Gazzola T, Carabelli G, Parati G. Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies. J Hypertens. 2013; 31:455–67.
- Lobstein T, Jackson-Leach R, Powis J, Brinsden H, Gray M. World Obesity Atlas 2023. United Kingdom: World Obesity Federation; 2023. [Accessed 2024 Mar 2]. Available from: https://policycommons.net/artifacts/3454894/untitled/4255209/
- Global report on hypertension: the race against a silent killer. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO. [Accessed 2024 Mar 2]. Available from: https://www.who.int/publications/i/item/9789240081062/
- Hall ME, Cohen JB, Ard JD, Egan BM, Hall JE, Lavie CJ, et al. Weight-loss strategies for prevention and treatment of hypertension: a scientific statement from the American Heart Association. Hypertension. 2021; 78:e38–e50.
- Chandra A. Global public health crises of obesity and hypertension: importance of prevention and treatment of obesity. 2021. American Heart Association; [Accessed 2024 Mar 2]. Available from: https://professional.heart.org/en/science-news/weight-loss-strategies-for-prevention-and-treatment-of-hypertension/Commentary
- Leggio M, Lombardi M, Caldarone E. The relationship between obesity and hypertension: an updated comprehensive overview on vicious twins. Hypertens Res. 2017; 40:947–96.
- Landsberg L, Aronne LJ, Beilin LJ. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of the Obesity Society and the American Society of Hypertension. J Clin Hypertens. 2013; 15:14–33.
- Jones DW, Kim JS, Andrew ME, Kim SJ, Hong YP. Body mass index and blood pressure in Korean men and women: the Korean national blood pressure survey. J Hypertens. 1994; 12:1433–7.
- Landi F, Calvani R, Picca A. Body mass index is strongly associated with hypertension: results from the longevity check-up 7+ study. Nutrients. 2018; 10:1976–87.
- DeMarco VG, Aroor AR, Sowers JR. The pathophysiology of hypertension in patients with obesity. Nat Rev Endocrinol. 2014; 10:364–76.
- Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017; 376:254–66.
- Wolk R, Shamsuzzaman AS, Somers VK. Obesity, sleep apnea, and hypertension. Hypertension. 2003; 42:1067–74.
- Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013; 177:1006–14.
- Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2000; 284:3015–21.
- Ihm SH. Pathophysiology and optimal management of hypertension in patients with cardiometabolic syndrome. Cardiometab Syndr J. 2021; 1:46–65.
- Ishigami J, Charleston J, Miller ER IIIrd, Matsushita K, Appel LJ, Brady TM. Effects of cuff size on the accuracy of blood pressure readings: the Cuff(SZ) Randomized Crossover Trial. JAMA Intern Med. 2023; 183:1061–8.
- Irving G, Holden J, Stevens R, McManus RJ. Which cuff should I use? Indirect blood pressure measurement for the diagnosis of hypertension in patients with obesity: a diagnostic accuracy review. BMJ Open. 2016; 6:e012429. doi: 10.1136/bmjopen-2016-012429
- Mendoza MF, Kachur SM, Lavie CJ. Hypertension in obesity. Curr Opin Cardiol. 2020; 35:389–96.
- Stevens VJ, Obarzanek E, Cook NR, Lee IM, Appel LJ, Smith West D, et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med. 2001; 134:1–11.
- Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure. Hypertension. 2003; 42:878–84.
- Semlitsch T, Krenn C, Jeitler K, Berghold A, Horvath K, Siebenhofer A. Long-term effects of weight-reducing diets in people with hypertension. Cochrane Database Syst Rev. 2021; 2:Cd008274. doi: 10.1002/14651858.CD008274.pub4
- Zomer E, Gurusamy K, Leach R, Trimmer C, Lobstein T, Morris S, et al. Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis. Obes Rev. 2016; 17:1001–11.
- Wadden TA, Tronieri JS, Butryn ML. Lifestyle modification approaches for the treatment of obesity in adults. Am Psychol. 2020; 75:235–51.
- Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society. J Am Coll Cardiol. 2014; 63:2985–3023.
- Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016; 22(Suppl 3):1–203.
- Cornier MA. A review of current guidelines for the treatment of obesity. Am J Manag Care. 2022; 28(15 Suppl):S288–S296.
- Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinical-Medicine. 2023; 58:101882. doi: 10.1016/j.eclinm.2023.101882
- Ansari HUH, Qazi SU, Sajid F, Altaf Z, Ghazanfar S, Naveed N, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: a systematic review and meta-analysis. Endocr Pract. 2024; 30:160–71.
- Muzurovića E, Mikhailidis DP. Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile. Expert Opin Pharmacother. 2020; 21:2125. doi: 10.1080/14656566.2020.1795132
- Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023; 389:2221–32.
- Omair A, Shariq OA, McKenzie TJ. Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery. Gland Surg. 2020; 9:80–93.
- Adams TD, Davidson LE, Litwin SE, Kim J, Kolotkin RL, Nanjee MN, et al. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med. 2017; 377:1143–55.
- American Diabetes Association Professional Practice Committee. 8 Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2024. Diabetes Care. 2024; 47(Suppl 1):S145–S157.
- Owen JG, Reisin E. Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications. Curr Hypertens Rep. 2015; 17:558. doi: 10.1007/s11906-015-0558-9
- Sharma AM, Pischon T, Engeli S, Scholze J. Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens. 2001; 19:667–74.
- Reisin E, Graves JW, Yamal JM, Barzilay JI, Pressel SL, Einhorn PT, et al. Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT. J Hypertens. 2014; 32:1503–13.
- Reisin E, Weir MR, Falkner B, Hutchinson HG, Anzalone DA, Tuck ML. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Hypertension. 1997; 30:140–5.
- NAVIGATOR Study Group; McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010; 362:1477. doi: 10.1056/NEJMoa1001121
- Gammone MA, Efthymakis K, D’Orazio N. Effect of third-generation beta blockers on weight loss in a population of overweight-obese subjects in a controlled dietary regimen. J Nutr Metab. 2021; 2021:5767306. doi: 10.1155/2021/5767306
- Neruntarat C, Chantapant S. Prevalence of sleep apnea in HRH Princess Maha Chakri Srinthorn Medical Center, Thailand. Sleep Breath. 2011; 15:641–8.
- Battaglia E, Banfi P, Compalati E, Nicolini A, Diaz DE Teran T, Gonzales M, et al. The pathogenesis of OSA-related hypertension: what are the determining factors? Minerva Med. 2024; 115:68–82.
- Mokhlesi B, Hagen EW, Finn LA, Hla KM, Carter JR, Peppard PE. Obstructive sleep apnoea during REM sleep and incident non-dipping of nocturnal blood pressure: a longitudinal analysis of the Wisconsin Sleep Cohort. Thorax. 2015; 70:1062–9.
- Ahmed AM, Nur SM, Xiaochen Y. Association between obstructive sleep apnea and resistant hypertension: systematic review and meta-analysis. Front Med (Lausanne). 2023; 10:1200952. doi: 10.3389/fmed.2023.1200952
- Kim D, Yang PS, Kim TH, Jang E, Shin H, Kim HY, et al. Ideal blood pressure in patients with atrial fibrillation. J Am Coll Cardiol. 2018; 72:1233–45.
- Stergiou GS, Kyriakoulis KG, Stambolliu E, Destounis A, Karpettas N, Kalogeropoulos P, et al. Blood pressure measurement in atrial fibrillation: review and meta-analysis of evidence on accuracy and clinical relevance. J Hypertens. 2019; 37:2430–41.
- Verberk WJ, Omboni S, Kollias A, Stergiou GS. Screening for atrial fibrillation with automated blood pressure measurement: research evidence and practice recommendations. Int J Cardiol. 2016; 203:465–73.
- Van Gelder IC, Rienstra M, Crijns HJ, Olshansky B. Rate control in atrial fibrillation. Lancet. 2016; 388:818–28.
- Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the losartan intervention for end point reduction in hypertension (LIFE) study. J Am Coll Cardiol. 2005; 45:712–9.
- Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, et al. CHARM investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Am Heart J. 2006; 152:86–92.
- Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 2010; 55:2299–307.
- Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA. 2006; 296:1242–8.
- ] Cikes M, Claggett B, Shah AM, Desai AS, Lewis EF, Shah SJ, et al. Atrial fibrillation in heart failure with preserved ejection fraction: the TOPCAT trial. JACC Heart Fail. 2018; 6:689–97.
- Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H, et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure) study. J Am Coll Cardiol. 2012; 59:1598–603.
- Zheng RJ, Wang Y, Tang JN, Duan JY, Yuan MY, Zhang JY. Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type 2 diabetes: a systemic review and meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol. 2022; 79:e145–e152.
- Pandey AK, Okaj I, Kaur H, Belley-Cote EP, Wang J, Oraii A, et al. Sodium-glucose co-transporter inhibitors and atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2021; 10:e022222. doi: 10.1161/JAHA.121.022222
- Arima H, Chalmers J. PROGRESS: prevention of recurrent stroke. J Clin Hypertens (Greenwich). 2011; 13:693–702.
- Lip GY, Frison L, Grind M, SPORTIF Invetigators. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J. 2007; 28:752–9.
- Rao MP, Halvorsen S, Wojdyla D, Thomas L, Alexander JH, Hylek EM, et al. Blood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. J Am Heart Assoc. 2015; 4:e002015. doi: 10.1161/JAHA.115.002015
- Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006; 367:1066–74.
- Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010; 376:631–44.
- Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. Obstet Gynecol. 2020; 135:e237–e260.
- Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2013; 2013:CD001449. doi: 10.1002/14651858.CD001449.pub3
- ACOG Committee Opinion No. 767: emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. Obstet Gynecol. 2019; 133:e174–e180.
- Chaemsaithong P, Biswas M, Lertrut W, Warintaksa P, Wataganara T, Poon LC, et al. Pharmacogenomics of preeclampsia therapies: current evidence and future challenges for clinical implementation. Best Pract Res Clin Obstet Gynaecol. 2024; 92:102437. doi: 10.1016/j. bpobgyn.2023.102437
- LeFevre ML, U.S. Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014; 161:819–26.
- Mahajan S, Zhang D, He S, Lu Y, Gupta A, Spatz ES, et al. Prevalence, awareness, and treatment of isolated diastolic hypertension: insights from the China PEACE Million Persons Project. J Am Heart Assoc. 2019; 8:e012954. doi: 10.1161/JAHA.119.012954
- Cho SMJ, Lee H, Kim HC. Differences in prevalence of hypertension subtypes according to the 2018 Korean Society of Hypertension and 2017 American College of Cardiology/American Heart Association guidelines: the Korean National Health and Nutrition Examination Survey, 2007-2017 (KNHANES IV-VII). Clin Hypertens. 2019; 25:26. doi: 10.1186/s40885-019-0129-5
- Huang M, Long L, Tan L, Shen A, Deng M, Peng Y, et al. Isolated diastolic hypertension and risk of cardiovascular events: a systematic review and meta-analysis of cohort studies with 489,814 participants. Front Cardiovasc Med. 2021; 8:810105. doi: 10.3389/fcvm.2021.810105
- McEvoy JW, Yang WY, Thijs L, Zhang ZY, Melgarejo JD, Boggia J, et al. Isolated diastolic hypertension in the IDACO study: an age-stratified analysis using 24-hour ambulatory blood pressure measurements. Hypertension. 2021; 78:1222–31.
- Suzuki Y, Kaneko H, Yano Y, Okada A, Matsuoka S, Fujiu K, et al. Reduction in blood pressure for people with isolated diastolic hypertension and cardiovascular outcomes. Eur J Prev Cardiol. 2023; 30:928–34.
- Mangoni AA, Jackson SH. Age-related changes in pharmaco-kinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004; 57:6–14.
- Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008; 358:1887–98.
- Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA. 2016; 315:2673–82.
- Liu X, Rodriguez CJ, Wang K. Prevalence and trends of isolated systolic hypertension among untreated adults in the United States. J Am Soc Hypertens. 2015; 9:197–205.
- Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000; 355:865–72.
- Sobieraj P, Lewandowski J, Siński M, Gaciong Z. Low on-treatment diastolic blood pressure and cardiovascular outcome: a post-hoc analysis using NHLBI SPRINT research materials. Sci Rep. 2019; 9:13070. doi: 10.1038/s41598-019-49557-4
- Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018; 72:e53–e90.
- Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008; 51:1403–19.
- Acelajado MC, Hughes ZH, Oparil S, Calhoun DA. Treatment of resistant and refractory hypertension. Circ Res. 2019; 124:1061–70.
- Roubsanthisuk W, Kunanon S, Chattranukulchai P, Panchavinnin P, Wongpraparut N, Chaipromprasit J, et al. 2022 Renal denervation therapy for the treatment of hypertension: a statement from the Thai Hypertension Society. Hypertens Res. 2023; 46:898–912.
- van den Born BH, Lip GYH, Brguljan-Hitij J, Cremer A, Segura J, Morales E, et al. ESC council on hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacother. 2019; 5:37–46.
- Slovis CM, Reddi AS. Increased blood pressure without evidence of acute end organ damage. Ann Emerg Med. 2008; 51:S7–S9.
- Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Hypertension. 2015; 65:1372–407.
- McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42:3599–726.
- Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE Jr, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. J Am Coll Cardiol. 2010; 55:e27–e129.
- Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361:1149–58.
- Andersson T, Nåtman J, Mourtzinis G, Bager JE, Bengtsson Boström K, Franzén S, et al. The effect of statins on mortality and cardiovascular disease in primary care hypertensive patients without other cardiovascular disease or diabetes. Eur J Prev Cardiol. 2023; 30:1883–94.
- Zheng S, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA. 2019; 321:277–87.
- Lin H, Guo Y, Zheng Y, Di Q, Liu T, Xiao J, et al. Long-term effects of ambient PM2.5 on hypertension and blood pressure and attributable risk among older Chinese adults. Hypertension. 2017; 69:806–12.
- Song J, Gao Y, Hu S, Medda E, Tang G, Zhang D, et al. Association of long-term exposure to PM2.5 with hypertension prevalence and blood pressure in China: a cross section study. BMJ Open. 2021; 11:e050159. doi: 10.1136/bmjopen-2021-050159
- Ye Z, Li X, Han Y, Wu Y, Fang Y. Association of long-term exposure to PM2.5 with hypertension and diabetes among the middle-aged and elderly people in Chinese mainland a spatial study. BMC Public Health. 2022; 22:569. doi: 10.1186/s12889-022-12984-6
- Rajagopalan S, Brauer M, Bhatnagar A, Bhatt DL, Brook JR, Huang W, et al. Personal-level protective actions against particulate matter air pollution exposure: a scientific statement from the American Heart Association. Circulation. 2020; 142:e411–e431.
- Omboni S, McManus RJ, Bosworth HB, Chappell LC, Green BB, Kario K, et al. Evidence and recommendations on the use of telemedicine for the management of arterial hypertension: an international expert position paper. Hypertension. 2020; 76:1368–83.
- Spatz ES, Ginsburg GS, Rumsfeld JS, Turakhia MP. Wearable digital health technologies for monitoring in cardiovascular medicine. N Engl J Med. 2024; 390:346–56.
- Chattranukulchai P, Thongtang N, Ophascharoensuk V, Muengtaweepongsa S, Angkurawaranon C, Chalom K, et al. An implementation framework for telemedicine to address noncommunicable diseases in Thailand. Asia Pac J Public Health. 2021; 33:968–71.
- Chattranukulchai P, Thongtang N, Kunanon S, Roubsanthisuk W, Angkurawaranon C, Leetongin G, et al. Implementing the implementation framework for telemedicine to address non-communicable diseases in Thailand: what we have learned. J Med Assoc Thai. 2023; 106:102–5.
- Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005; 294:466–72.
- Kokubo Y, Kamide K, Okamura T, Watanabe M, Higashiyama A, Kawanishi K, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease in a Japanese urban cohort: the Suita study. Hypertension. 2008; 52:652–9.
- Asayama K, Ohkubo T, Yoshida S, Suzuki K, Metoki H, Harada A, et al. Stroke risk and antihypertensive drug treatment in the general population: the Japan Arteriosclerosis Longitudinal Study. J Hypertens. 2009; 27:357–64.
- Agawal R, Bills JE, Hecth Tyler JW, Light RP. Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis. Hypertension. 2011; 57:29–38.
- Egan BM, Sutherland SE, Rakotz M, Yang J, Hanlin RB, Davis RA, et al. Improving hypertension control in primary care with the measure accurately, act rapidly, and partner with patients protocol. Hypertension. 2018; 72:1320–7.
- Lebeau JP, Cadwallader JS, Aubin-Auger I, Mercier A, Pasquet T, Rusch E, et al. The concept and definition of therapeutic inertia in hypertension in primary care: a qualitative systemic review. BMC Fam Pract. 2014; 15:130. doi: 10.1186/1471-2296-15-130
- Zhao J, Hu Y, Zhang X, Zhang G, Lin M, Chen X, et al. Efficacy of empowerment strategies for patients with hypertension: a systematic review and meta-analysis. Patient Educ Couns. 2020; 103:898–907.